Lymphoma & CLL Trials

Outpatient administration of liso-cel: Preliminary results from the OUTREACH study

Due to concerns regarding adverse events (AEs), chimeric antigen receptor (CAR) T-cell therapies are predominantly...

Liso-cel treatment in the outpatient setting

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, Carlos Bachier presented the results of a study evaluating the safety and...

Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL

On March 25, 2021, it was announced that duvelisib received a positive opinion from the European...

Results from the phase III DUO trial on duvelisib for relapsed/refractory CLL/SLL

This sphase III trial demonstrated that duvelisib treatment in R/R CLL/SLL patients results in significantly longer...

Real-world outcomes in Germany with standard-of-care axi-cel and tisa-cel for large B-cell lymphoma

Following promising results in clinical trials, the CD19-targeted chimeric antigen receptor (CAR)...

Japanese approval of axicabtagene ciloleucel for the treatment of R/R large B-cell lymphomas

On January 22, 2021, it was announced that the Japanese Ministry of Health, Labour and Welfare approved the...

FDA biologics license application of ublituximab plus umbralisib for the treatment of CLL

On March 29, 2021, it was announced that a biologics license application (BLA) was submitted to the U.S. Food...

Umbralisib and ublituximab combination is superior to current standard of care for patients with untreated, relapsed, or refractory CLL

The synergistic activity of umbralisib, a dual inhibitor of...